BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18589448)

  • 1. Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus.
    Chase HP; Arslanian S; White NH; Tamborlane WV
    J Pediatr; 2008 Oct; 153(4):547-53. PubMed ID: 18589448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes.
    White NH; Chase HP; Arslanian S; Tamborlane WV;
    Diabetes Care; 2009 Mar; 32(3):387-93. PubMed ID: 19106380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.
    Bolli GB; Songini M; Trovati M; Del Prato S; Ghirlanda G; Cordera R; Trevisan R; Riccardi G; Noacco C
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):571-9. PubMed ID: 18676131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR; Gilbert RE; Yue DK
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens.
    Murphy NP; Keane SM; Ong KK; Ford-Adams M; Edge JA; Acerini CL; Dunger DB
    Diabetes Care; 2003 Mar; 26(3):799-804. PubMed ID: 12610040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes.
    Garg SK; Paul JM; Karsten JI; Menditto L; Gottlieb PA
    Diabetes Technol Ther; 2004 Oct; 6(5):589-95. PubMed ID: 15628812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin.
    Chase HP; Dixon B; Pearson J; Fiallo-Scharer R; Walravens P; Klingensmith G; Rewers M; Garg SK
    J Pediatr; 2003 Dec; 143(6):737-40. PubMed ID: 14657818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
    Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P
    Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study.
    Fonseca V; Bell DS; Berger S; Thomson S; Mecca TE
    Am J Med Sci; 2004 Nov; 328(5):274-80. PubMed ID: 15545844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy].
    Pesić M; Zivić S; Radenković S; Velojić M; Dimić D; Antić S
    Vojnosanit Pregl; 2007 Apr; 64(4):247-52. PubMed ID: 17580534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
    Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
    Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes.
    Hershon KS; Blevins TC; Mayo CA; Rosskamp R
    Endocr Pract; 2004; 10(1):10-7. PubMed ID: 15251616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Fritsche A; Schweitzer MA; Häring HU;
    Ann Intern Med; 2003 Jun; 138(12):952-9. PubMed ID: 12809451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
    Bolli GB; Kerr D; Thomas R; Torlone E; Sola-Gazagnes A; Vitacolonna E; Selam JL; Home PD
    Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.
    Imbergamo MP; Amato MC; Sciortino G; Gambina M; Accidenti M; Criscimanna A; Giordano C; Galluzzo A
    Clin Ther; 2008 Aug; 30(8):1476-84. PubMed ID: 18803989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
    Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes.
    Home PD; Rosskamp R; Forjanic-Klapproth J; Dressler A;
    Diabetes Metab Res Rev; 2005; 21(6):545-53. PubMed ID: 16021649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
    Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
    Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.